Dermira Inc. (NASDAQ:DERM)‘s stock had its “positive” rating restated by analysts at Needham & Company LLC in a note issued to investors on Monday. They currently have a $46.00 price objective on the biopharmaceutical company’s stock. Needham & Company LLC’s target price would indicate a potential upside of 32.30% from the company’s current price.
Separately, Zacks Investment Research upgraded Dermira from a “sell” rating to a “hold” rating in a report on Tuesday, June 14th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $41.00.
Shares of Dermira (NASDAQ:DERM) opened at 34.77 on Monday. Dermira has a 52 week low of $17.42 and a 52 week high of $36.16. The firm has a 50-day moving average price of $33.01 and a 200-day moving average price of $29.42. The stock’s market cap is $1.23 billion.
Dermira (NASDAQ:DERM) last released its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.89) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by $0.03. On average, analysts forecast that Dermira will post ($3.39) earnings per share for the current fiscal year.
In related news, VP Christopher M. Griffith sold 1,303 shares of the firm’s stock in a transaction dated Friday, July 15th. The stock was sold at an average price of $30.02, for a total transaction of $39,116.06. Following the sale, the vice president now directly owns 44,941 shares in the company, valued at approximately $1,349,128.82. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Andrew Guggenhime sold 10,000 shares of the firm’s stock in a transaction dated Monday, July 11th. The shares were sold at an average price of $30.15, for a total value of $301,500.00. Following the sale, the chief financial officer now owns 14,375 shares in the company, valued at $433,406.25. The disclosure for this sale can be found here. Corporate insiders own 17.30% of the company’s stock.
Large investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. raised its stake in shares of Dermira by 6,034.5% in the second quarter. JPMorgan Chase & Co. now owns 3,558 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 3,500 shares during the period. Glenmede Trust Co. NA acquired a new stake in shares of Dermira during the second quarter worth $170,000. A.R.T. Advisors LLC acquired a new stake in shares of Dermira during the second quarter worth $207,000. DIAM Co. Ltd. acquired a new stake in shares of Dermira during the second quarter worth $231,000. Finally, Prudential Financial Inc. acquired a new stake in shares of Dermira during the second quarter worth $253,000. Institutional investors and hedge funds own 82.46% of the company’s stock.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.